# OnCo record alpelisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/alpelisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "alpelisib" ;
  schema:name "Alpelisib"@en ;
  schema:description "Alpelisib was the first PI3K drug for PIK3CA-mutant breast cancer (2019). It is effective, but high blood sugar and rash limited its use, and newer drugs are displacing it."@en ;
  schema:url <https://onco.cc/drugs/alpelisib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Alpelisib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27074391> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Alpelisib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule PI3Kα inhibitor" ;
  schema:alternateName "Piqray" ;
  onco:approval "US 2019: PIK3CA-mutant HR+/HER2- advanced breast cancer with fulvestrant after endocrine therapy" ;
  onco:acceleratedApproval "US 2022-04-05: Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy", "US 2024-04-24: Formulation: Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy." ;
  onco:related <https://onco.cc/biomarkers/er-status/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/hyperglycaemia/> ;
  onco:trials <https://onco.cc/trials/solar-1/>, <https://onco.cc/trials/nct05501886/>, <https://onco.cc/trials/nct04208178/>, <https://onco.cc/trials/nct05948943/>, <https://onco.cc/trials/nct05563220/>, <https://onco.cc/trials/nct05646862/>, <https://onco.cc/trials/nct05230810/>, <https://onco.cc/trials/nct05038735/>, <https://onco.cc/trials/nct04524000/>, <https://onco.cc/trials/nct04544189/> .